These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 29460260)

  • 21. Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
    Yin TT; Bi Y; Li P; Shen SM; Xiong XL; Gao LJ; Jiang C; Wang Y; Feng WH; Zhu DL
    Diabetes Ther; 2018 Jun; 9(3):1253-1267. PubMed ID: 29744819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
    Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
    Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Zhou W; Tao J; Zhou X; Chen H
    Diabetes Ther; 2019 Jun; 10(3):835-852. PubMed ID: 31020539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
    Berard L; MacNeill G
    Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.
    Dżygało K; Golicki D; Kowalska A; Szypowska A
    Acta Diabetol; 2015 Apr; 52(2):231-8. PubMed ID: 25430705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review.
    Cheng AYY; Wong J; Freemantle N; Acharya SH; Ekinci E
    Diabetes Ther; 2020 Nov; 11(11):2555-2593. PubMed ID: 32975710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical safety of insulin detemir in patients with Type 2 diabetes in the Gulf countries: The multicenter, noninterventional, open-label LevSafe study.
    El Shiekh AR; Farrag HA; Ashour T; Alshali KZ; AbdelFattah W
    Indian J Endocrinol Metab; 2016; 20(4):443-50. PubMed ID: 27366709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year safety and effectiveness of insulin degludec in patients with diabetes mellitus in routine clinical practice in India-TRUST (Tresiba real-world use study).
    Kesavadev J; Murthy LS; Chaudhury T; Yalamanchi SR; Giri J; Gupta S; Phatak S; Modi KD; Chatterjee S; Manjunath A; Revanna M; Bhattacharya A
    Metabol Open; 2022 Jun; 14():100184. PubMed ID: 35496980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Type 2 Diabetes With Insulin Glargine-100 in Iraq in a Real-Life Observation.
    Mansour AA; Rahmah A; Khudhair M
    Cureus; 2022 Nov; 14(11):e31164. PubMed ID: 36483894
    [No Abstract]   [Full Text] [Related]  

  • 31. Author Correction: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study.
    Bjekić-Macut J; Živković TB; Kocić R
    Diabetes Ther; 2018 Apr; 9(2):663. PubMed ID: 29569224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion.
    Bajaj S; Das AK; Kalra S; Sahay R; Saboo B; Das S; Shunmugavelu M; Jacob J; Priya G; Khandelwal D; Dutta D; Chawla M; Surana V; Tiwaskar M; Joshi A; Shrestha PK; Bhattarai J; Bhowmik B; Latt TS; Aye TT; Vijayakumar G; Baruah M; Jawad F; Unnikrishnan AG; Chowdhury S; Pathan MF; Somasundaram N; Sumanathilaka M; Raza A; Bahendeka SK; Coetzee A; Ruder S; Ramaiya K; Lamptey R; Bavuma C; Shaikh K; Uloko A; Chaudhary S; Abdela AA; Akanov Z; Rodrìguez-Saldaña J; Faradji R; Tiago A; Reja A; Czupryniak L
    Diabetes Ther; 2019 Aug; 10(4):1189-1204. PubMed ID: 31102253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020.
    Hankosky ER; Schapiro D; Gunn KB; Lubelczyk EB; Mitroi J; Nelson DR
    Diabetes Ther; 2023 Jun; 14(6):967-975. PubMed ID: 37067668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis.
    Ascher-Svanum H; Zagar A; Jiang D; Schuster D; Schmitt H; Dennehy EB; Kendall DM; Raskin J; Heine RJ
    Diabetes Ther; 2015 Sep; 6(3):303-16. PubMed ID: 26159935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus.
    Zografou I; Strachan M; McKnight J
    Hippokratia; 2014; 18(4):306-9. PubMed ID: 26052195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of glycated hemoglobin during treatment with insulin analogues dispensed in the public health system of Federal District in Brazil.
    Leite EB; Pedrosa HC; Casulari LA
    Diabetol Metab Syndr; 2015; 7():66. PubMed ID: 26288660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico.
    Lavalle-González FJ; Chiquete E
    Patient Prefer Adherence; 2016; 10():1349-57. PubMed ID: 27555751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel.
    Chawla M; Jain SM; Kesavadev J; Makkar BM; Viswanathan V; Tiwaskar M; Sosale AR; Negalur V; Modi KD; Gupta M; Kumar S; Ramakrishnan S; Deka N; Roy N
    Diabetes Ther; 2021 Jan; 12(1):133-142. PubMed ID: 33314000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Level of Glycemic Control and Clinical Inertia in Subjects Using Insulin for the Treatment of Type 1 and Type 2 Diabetes in the Czech Republic and the Slovak Republic: Results of a Multinational, Multicenter, Observational Survey (DIAINFORM).
    Brož J; Janíčková Žďárská D; Urbanová J; Brabec M; Doničová V; Štěpánová R; Martinka E; Kvapil M
    Diabetes Ther; 2018 Oct; 9(5):1897-1906. PubMed ID: 30094784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EFFICACY AND SAFETY OF BASAL INSULIN THERAPY IN ROMANIAN PATIENTS WITH TYPE 2 DIABETES IN REAL-LIFE SETTINGS: A SUB-GROUP ANALYSIS OF DUNE STUDY.
    Cerghizan A; Amorin P; Catrinoiu D; Creteanu G; Adamescu E; Moise M
    Acta Endocrinol (Buchar); 2020; 16(1):43-48. PubMed ID: 32685037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.